http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0853450-A4

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_204f3e2308fd9f958a2da05c209279ae
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
filingDate 1996-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4c9b1370bd8cf20b8b55cfac1f809ca
publicationDate 2003-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0853450-A4
titleOfInvention TREATMENT OF VASCULAR INJURIES
abstract The present invention provides a method for inducing reendothelialization of the lining of an injured blood vessel comprising contacting the injured portion of the vessel with nucleic acid encoding an endothelial cell mitogen such as vascular endothelial growth factor (VEGF) operably linked to a promoter to result in expression of the mitogen when delivered to the cells at the site of vascular injury. The resulting reendothelialization of the injured blood vessel inhibits smooth muscle cell proliferation and consequently reduces restenosis. The methods of the present invention may be used to treat any blood vessel injury that results in denuding of the endothelial lining of the vessel wall, including, for example, those injuries resulting from balloon angioplasty and deployment of endovascular stents.
priorityDate 1995-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9503083-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409987
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406322
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6060
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405927
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6249
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57199466
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423425
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID231027909
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3821
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6077
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405859
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18403964
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226426032
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406750
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2244
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8588
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226402238
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6032
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14710
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394110
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5707
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226425017
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406323
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11105
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644025
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395099
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226453110

Total number of triples: 48.